Eli Lilly posts Q3 2026 revenue of $24.4 billion, lifts full‑year outlook to $91‑92 billion
Eli Lilly reported third‑quarter 2026 revenue of $24.4 billion, up about 39% year‑over‑year, driven by strong sales of its GLP‑1 drugs Mounjaro and Zepbound. The company raised its full‑year 2026 revenue guidance to a range of $91 billion‑$92 billion, higher than the prior $85‑$87 billion outlook. Management said the quarter exceeded earlier expectations and highlighted continued growth in its obesity franchise.
Why it matters
The higher revenue guidance expands the market’s expectations for Lilly’s 2026 earnings, which could support a higher valuation for the stock. Analysts such as Cantor Fitzgerald and Morgan Stanley have lifted their price targets in response, indicating potential upside for investors.
Key facts
- 1Q3 2026 revenue was $24.40 billion, a 38.6% increase from the prior year. 247wallst.com
- 2Mounjaro generated $10.72 billion in sales, up 65%, and Zepbound generated $5.35 billion, up 49%. 247wallst.com
- 3Full‑year 2026 revenue guidance was raised to $91 billion‑$92 billion from $85 billion‑$87 billion. 247wallst.com
- 4Non‑GAAP EPS for the quarter was $7.48, beating the $6.67 estimate. 247wallst.com
- 5Cantor Fitzgerald increased its price target to $1,600 from $1,440. investing.com
- 6Morgan Stanley raised its price target to $1,596 from $1,430. finance.yahoo.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.